1. Home
  2. BPMC

BPMC

Blueprint Medicines Corporation

Logo Blueprint Medicines Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Founded: 2008 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 5.5B IPO Year: 2015
Target Price: $83.86 AVG Volume (30 days): 776.3K
Analyst Decision: Buy Number of Analysts: 14
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -8.37 EPS Growth: N/A
52 Week Low/High: $43.89 - $101.00 Next Earning Date: 05-02-2024
Revenue: $249,380,000 Revenue Growth: 22.22%
Revenue Growth (this year): 60.63% Revenue Growth (next year): 51.77%

Share on Social Networks: